<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; use</title>
	<atom:link href="http://www.tapanray.in/tag/use/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Create Novel Marketing Pathways As Covid Mutants Keep Emerging</title>
		<link>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-novel-marketing-pathways-as-covid-mutants-keep-emerging</link>
		<comments>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/#comments</comments>
		<pubDate>Mon, 10 Jan 2022 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approvals]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[EUA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molnupiravir]]></category>
		<category><![CDATA[mutants]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[variants]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10634</guid>
		<description><![CDATA[The World’s battle against wave after wave unsettling onslaught of Coronavirus on human lives and livelihood continues, since December 2019. The first wave was triggered by the novel Covid-19 from Wuhan in China, the second by its deadly – Delta variant, &#8230; <a href="http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exploring An Exit To India’s Covid Management Maze</title>
		<link>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploring-an-exit-to-indias-covid-management-maze</link>
		<comments>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/#comments</comments>
		<pubDate>Mon, 03 May 2021 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covaxin]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[imported]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian Patent Act]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[maze]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 100]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10487</guid>
		<description><![CDATA[‘India’s Covid-19 Crisis is Spiraling Out of Control. It Didn’t Have to Be This Way,’ was the headline of the lead article, published in The Time with the cover page ‘India in Crisis.’ All Indians also believe the same, as the current &#8230; <a href="http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescription Digital Therapy Now A Reality</title>
		<link>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescription-digital-therapy-now-a-reality</link>
		<comments>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/#comments</comments>
		<pubDate>Mon, 07 May 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2]]></category>
		<category><![CDATA[3]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[cognition]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[mood]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[Pear]]></category>
		<category><![CDATA[Pears]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[scope]]></category>
		<category><![CDATA[seizures]]></category>
		<category><![CDATA[Substance]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[wealthy]]></category>
		<category><![CDATA[wearable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8981</guid>
		<description><![CDATA[The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company &#8230; <a href="http://www.tapanray.in/prescription-digital-therapy-now-a-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescription-digital-therapy-now-a-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Off-label Use of Drugs: A Path Much Abused?</title>
		<link>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-off-label-use-of-drugs-a-path-much-abused</link>
		<comments>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/#comments</comments>
		<pubDate>Mon, 30 Nov 2015 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abused]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[cities]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[methods]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[opposes]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[records]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[usages]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7296</guid>
		<description><![CDATA[As many would know, prescribing any medicine for disease conditions that are not approved by the drug approving authorities while granting its marketing approval, is generally termed as ‘off-label’ use of drugs. It is also a usual practice in most &#8230; <a href="http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-off-label-use-of-drugs-a-path-much-abused/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should India allow use of Compulsory License as a common tool to improve access to medicines?</title>
		<link>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines</link>
		<comments>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/#comments</comments>
		<pubDate>Mon, 20 Aug 2012 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[allow]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=48</guid>
		<description><![CDATA[Compulsory License (CL) is generally considered a very important provision in the Patent Act of a country to protect public health interest not only by the governments, but also by a large number of experts across the globe and the &#8230; <a href="http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-india-allow-use-of-compulsory-license-as-a-common-tool-to-improve-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Indian patients victims of “unnecessary tests and procedures, rewards for referrals and irrational use of drugs?” A perspective</title>
		<link>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective</link>
		<comments>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/#comments</comments>
		<pubDate>Mon, 24 Jan 2011 01:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[procedures]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[referrals]]></category>
		<category><![CDATA[rewards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tests]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[victims]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=311</guid>
		<description><![CDATA[Since quite some time, serious concerns have been expressed by the media, government and the civil society at large about the means adopted by the pharmaceutical industry in general to get their respective brands prescribed by the doctors and why &#8230; <a href="http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Contract Research – a rapidly evolving business opportunity in India: Is the Pharmaceutical Industry making the best use of it?</title>
		<link>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it</link>
		<comments>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 01:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rapidly]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=845</guid>
		<description><![CDATA[A quick perspective of the ‘new-era’ pharmaceutical R&#38;D in India: Since 1970 up until 2005, Indian pharmaceutical industry used to be considered as the industry of ‘reverse engineering’ and that too with an underlying disparaging tone&#8230; and also as the &#8230; <a href="http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative use of the new-age ‘Social cyber-media’ as a pharmaceutical marketing tool has the potential to open a goldmine of opportunities.</title>
		<link>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities</link>
		<comments>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/#comments</comments>
		<pubDate>Thu, 25 Jun 2009 01:30:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[goldmine]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[new-age]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=851</guid>
		<description><![CDATA[The new-age marketing tool: With more and more doctors not giving adequate time and even showing reluctance to meet the medical representatives and the important hospitals following suit, the global pharmaceutical companies are now in search of new marketing tools. &#8230; <a href="http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
